SDZ Stock Analysis: Sandoz | SW
Drug Manufacturers - Specialty & Generic | SW, Switzerland | Market Cap: 30.730m CHF | 12M Return: 48.1% | CH1243598427 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 88.4M
Rev. Trend: 62.5%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sandoz Group AG is a Switzerland-based pharmaceutical company that develops, manufactures, and markets generic and biosimilar medicines worldwide. Founded in 1886 and headquartered in Basel, the company operates across a broad range of therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology.
Beyond finished dosage forms, Sandoz produces active pharmaceutical ingredients (APIs) and maintains a strategic collaboration with Shanghai Henlius Biotech, Inc. to expand global patient access to biosimilar medicines. The company is a large-cap player in the specialty and generic drug manufacturing sector, an industry characterized by producing off-patent small-molecule drugs and near-identical versions of biologic therapies once original patents expire.
- Biosimilars revenue accelerates as key launches scale
- US generic pricing erosion pressures gross margins
- European generics volume offsets inflationary cost pressures
| Net Income: 648.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 3.27 > 1.0 |
| NWC/Revenue: 3.88% < 20% (prev 20.35%; Δ -16.46% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.92b > Net Income 648.3m |
| Net Debt (5.32b) to EBITDA (2.34b): 2.27 < 3 |
| Current Ratio: 1.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (438.4m) vs 12m ago 1.43% < -2% |
| Gross Margin: 47.54% > 18% (prev 46.60%; Δ 0.93% > 0.5%) |
| Asset Turnover: 51.91% > 50% (prev 43.15%; Δ 8.76% > 0%) |
| Interest Coverage Ratio: 8.15 > 6 (EBIT TTM 1.76b / Interest Expense TTM 215.6m) |
| A: 0.02 (Total Current Assets 8.81b - Total Current Liabilities 8.36b) / Total Assets 22.9b |
| B: 0.37 (Retained Earnings 8.43b / Total Assets 22.9b) |
| C: 0.08 (EBIT TTM 1.76b / Avg Total Assets 22.2b) |
| D: 0.65 (Book Value of Equity 9.02b / Total Liabilities 13.8b) |
| Altman-Z'' = 2.55 = A |
| DSRI: 0.88 (Receivables 2.95b/2.69b, Revenue 11.5b/9.32b) |
| GMI: 0.98 (GM 46.60% / 47.54%) |
| AQI: 0.94 (AQ_t 0.49 / AQ_t-1 0.52) |
| SGI: 1.24 (Revenue 11.5b / 9.32b) |
| TATA: -0.06 (NI 648.3m - CFO 1.92b) / TA 22.9b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of October 14, 2026, the stock is trading at CHF 71.64 with a total of 790,426 shares traded. Over the past week, the price has changed by +2.69%, over one month by +7.73%, over three months by +7.47% and over the past year by +48.10%.
Current recommended Stop Loss: 69.00 (which is 3.7% or 1.3 ATR below the current price).
Sandoz has no consensus analysts rating.
Market Cap USD = 36.8b (30.7b CHF * 1.1982 CHF.USD)
P/E Trailing = 61.7565
P/E Forward = 18.9394
P/S = 2.6319
P/B = 4.1811
P/EG = 1.1107
Revenue TTM = 11.5b USD
EBIT TTM = 1.76b USD
EBITDA TTM = 2.34b USD
Long Term Debt = 4.46b USD (from longTermDebt, last quarter)
Short Term Debt = 1.45b USD (from shortTermDebt, last quarter)
Debt = 6.57b USD (from shortLongTermDebtTotal, last quarter) + Leases 352.0m
Net Debt = 5.32b USD (calculated: Debt 6.57b - CCE 1.25b)
Enterprise Value = 42.1b USD (36.8b + Debt 6.57b - CCE 1.25b)
Interest Coverage Ratio = 8.15 (Ebit TTM 1.76b / Interest Expense TTM 215.6m)
EV/FCF = 38.95x (Enterprise Value 42.1b / FCF TTM 1.08b)
FCF Yield = 2.57% (FCF TTM 1.08b / Enterprise Value 42.1b)
FCF Margin = 9.37% (FCF TTM 1.08b / Revenue TTM 11.5b)
Net Margin = 5.62% (Net Income TTM 648.3m / Revenue TTM 11.5b)
Gross Margin = 47.54% ((Revenue TTM 11.5b - Cost of Revenue TTM 6.05b) / Revenue TTM)
Gross Margin QoQ = 46.61% (prev 48.43%)
Tobins Q-Ratio = 1.84 (Enterprise Value 42.1b / Total Assets 22.9b)
Interest Expense / Debt = 3.28% (Interest Expense 215.6m / Debt 6.57b)
Taxrate = 23.20% (195.8m / 844.2m)
NOPAT = 1.35b (EBIT 1.76b * (1 - 23.20%))
Current Ratio = 1.05 (Total Current Assets 8.81b / Total Current Liabilities 8.36b)
Debt / Equity = 0.73 (Debt 6.57b / totalStockholderEquity, last quarter 9.02b)
Debt / EBITDA = 2.27 (Net Debt 5.32b / EBITDA 2.34b)
Debt / FCF = 4.92 (Net Debt 5.32b / FCF TTM 1.08b)
Total Stockholder Equity = 8.85b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.92% (Net Income 648.3m / Total Assets 22.9b)
RoE = 7.33% (Net Income TTM 648.3m / Total Stockholder Equity 8.85b)
RoCE = 13.20% (EBIT 1.76b / Capital Employed (Equity 8.85b + L.T.Debt 4.46b))
RoIC = 8.78% (NOPAT 1.35b / Invested Capital 15.4b)
WACC = 7.32% (E(36.8b)/V(43.4b) * Re(8.18%) + D(6.57b)/V(43.4b) * Rd(3.28%) * (1-Tc(0.23)))
Discount Rate = 8.18% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.22 | Cagr: 0.82%
[DCF] Terminal Value 77.97% ; FCFF base≈775.5m ; Y1≈888.9m ; Y5≈1.31b
[DCF] Fair Price = 33.21 (EV 19.7b - Net Debt 5.32b = Equity 14.4b / Shares 432.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 62.45 | Revenue CAGR: 14.72% | SUE: 1.61 | # QB: 1
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=4.09 | Chg30d=-0.53% | Revisions=-22% | GrowthEPS=+12.3% | GrowthRev=+9.2%
EPS next Year (2027-12-31): EPS=4.58 | Chg30d=-0.65% | Revisions=-12% | GrowthEPS=+12.0% | GrowthRev=+5.3%
[Analyst] Revisions Ratio: -21% (up=4, down=7)